Streetbeat News

Products Services

ENDPQ

PINC

Endo International plc (OTC:ENDPQ) and Premier, Inc. (NASDAQ:PINC) have announced a collaboration to address the shortage of Pitocin, a critical labor and delivery drug. Endo's Par Sterile Products business will supply Pitocin vials through Premier's ProvideGx and PremierProRx programs. The partnership aims to provide a stable product supply and enhance pricing predictability.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:32 pm

CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced positive results from a Phase 1b study of its proprietary cortisol modulator, miricorilant, in patients with non-alcoholic steatohepatitis (NASH). The study found that patients who received 100 mg of miricorilant twice a week for 12 weeks experienced a 30% reduction in liver fat and improvements in liver enzymes and markers of liver disease. The company plans to initiate a Phase 2b trial in the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:14 pm

ARDS

Aridis Pharmaceuticals has received approval from the European Medicines Agency (EMA) for the clinical study design and a single confirmatory Phase 3 study of AR-301. This is a significant step forward for the company's drug development program.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:09 pm

FDMT

4D Molecular Therapeutics has completed the enrollment of 50 patients for its Phase 2 PRISM clinical trial for 4D-150, a treatment for Wet AMD. The enrollment was completed two quarters ahead of initial projections. No serious adverse events or deviations from the protocol were reported. Initial interim Phase 2 efficacy data is expected to be presented in H1 2024, and an update regarding Phase 3 pivotal trial plans is expected in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:07 pm

KPTI

Karyopharm has secured FDA Fast Track Designation for Selinexor for the treatment of Myelofibrosis. This designation highlights the potential of Selinexor to address the unmet medical need in myelofibrosis.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:07 pm

WOLF

Wolfspeed, Inc. (NYSE:WOLF) has confirmed that its supply chain will not be affected by the Chinese Ministry of Commerce's decision to restrict the export of gallium and germanium, effective from August 1, 2023. The company will continue to review its supply chain periodically to ensure its needs are met.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 8:05 pm

MDWD

MediWound Ltd. has signed a scale-up agreement with Biopharmax Group Ltd. to establish a state-of-the-art manufacturing facility and increase production capacity to meet the growing global demand for Nexobrid. An estimated $12M will be invested in the project.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 8:05 pm

MDWD

MediWound Ltd. has signed a scale-up agreement with Biopharmax Group Ltd. to establish a state-of-the-art manufacturing facility and increase production capacity to meet the growing global demand for Nexobrid. An estimated $12M will be invested in the project.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 8:05 pm

MLYS

Mineralys Therapeutics plans to expand its Phase 2 trial of lorundrostat, alone and in combination with an SGLT2 inhibitor, to treat patients with Chronic Kidney Disease (CKD). The trial is set to begin in the second half of 2023. A safety profiling trial for individuals with stage 3b and 4 CKD will run in parallel.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 8:03 pm

FSR

Fisker Inc. has announced plans to produce 100 Fisker Extreme Vigyan Edition all-electric SUVs for the Indian market. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 7:56 pm